Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study-Reference-Cited by-同舟云学术

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Published:2024-06 Issue:6 Volume:19 Page:928-940
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nassar Amin H.,Kim So Yeon,Aredo Jacqueline V.,Feng Jamie,Shepherd Frances,Xu Chao,Kaldas David,Gray Jhanelle E.,Dilling Thomas J.,Neal Joel W.,Wakelee Heather A.,Liu Yufei,Lin Steven H.,Abuali Tariq,Amini Arya,Nie Yunan,Patil Tejas,Lobachov Anastasiya,Bar Jair,Fitzgerald Bailey,Fujiwara Yu,Marron Thomas U.,Thummalapalli Rohit,Yu Helena,Owen Dwight H.,Sharp John,Farid Saira,Rocha Pedro,Arriola Edurne,D’Aiello Angelica,Cheng Haiying,Whitaker Ryan,Parikh Kaushal,Ashara Yash,Chen Luxi,Sankar Kamya,Harris Jeremy P.,Nagasaka Misako,Ayanambakkam Adanma,Velazquez Ana I.,Ragavan Meera,Lin Jessica J.,Piotrowska Zofia,Wilgucki Molly,Reuss Joshua,Luders Heike,Grohe Christian,Baena Espinar Javier,Feiner Ella,Punekar Salman R.,Gupta Shruti,Leal Ticiana,Kwiatkowski David J.,Mak Raymond H.,Adib Elio^ORCID,Naqash Abdul Rafeh,Goldberg Sarah B.

Publisher

Elsevier BV

Reference20 articles.

2. Cancer treatment and survivorship statistics, 2022;Miller;CA Cancer J Clin,2022

3. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

4. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC;Antonia;N Engl J Med,2018

5. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer;Jung;Lung Cancer,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recapping Radiation Related Abstracts at ASCO 2024: A Commentary about the Fundamental Role of Radiation Therapy in Esophageal and Lung Cancers;International Journal of Radiation Oncology*Biology*Physics;2024-10

2. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario;Current Oncology;2024-08-30

3. Advances and future directions in ROS1 fusion-positive lung cancer;The Oncologist;2024-08-23

4. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC;New England Journal of Medicine;2024-08-15

5. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC;The Oncologist;2024-05-18